Aimee Tharaldson, PharmD

In 2018, watch for novel cancer drugs and several new orphan drugs to affect the market.

New treatments for inflammatory conditions, cancer, and HIV are on the horizon. 

During the first half of 2016, the FDA approved several new specialty medications.

New therapies on the horizon for cancer, multiple sclerosis, and rheumatoid arthritis.

Approvals expected for new drugs to treat bladder cancer and advanced ER+ breast can­cer.

Approvals for new drugs to treat orphan conditions and asthma are expected.

Anticipated near-term specialty drug approvals include new therapies for cancer, orphan conditions, high cholesterol, and asthma.

Drug approvals on the horizon include new therapies for cancer, high cholesterol, idiopathic pulmonary fibrosis, and hepatitis C.

Approval is expected in 2014 for drugs to treat psoriasis, cancer, and orphan conditions.

Therapies for hepatitis C, cancer, and orphan conditions are among the specialty drugs expected to receive approval in 2014.

Specialty medications on the path to approval include 2 new hepatitis drugs.

A significant number of new specialty medications are on track to be approved in 2013, and some will provide increased competition in certain therapy classes.

A significant number of new specialty medications are on track to be approved in 2013, and some will provide increased competition in certain therapy classes.

In 2012, the FDA approved 22 specialty medications, up from 18 specialty drug approvals in 2011. This trend is expected to continue for the forseeable future.

By the end of this year, it is likely that the FDA will approve more than 20 new specialty medications.